What is RoosterBio?
Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio operates as a specialized cell manufacturing platform technology company. The firm is dedicated to the industrialization of regenerative medicine, providing standardized, high-quality cell products that streamline the development process for therapeutic developers. By shifting the paradigm from bespoke, small-scale production to scalable, off-the-shelf solutions, RoosterBio serves as a vital enabler for the next generation of life-saving therapies. Its market position is defined by its ability to reduce time-to-market for customers, effectively acting as a foundational utility for the burgeoning bioeconomy.
How much funding has RoosterBio raised?
RoosterBio has raised a total of $35.9M across 6 funding rounds:
Private Equity
$5.2M
Debt
$1.3M
Series A
$6M
Series B
$21.5M
Debt
$1M
Debt
$990K
Private Equity (2016): $5.2M, investors not publicly disclosed
Debt (2017): $1.3M, investors not publicly disclosed
Series A (2017): $6M, investors not publicly disclosed
Series B (2019): $21.5M featuring Vanedge Capital, Dynamk Capital, and Bioeconomy Capital
Debt (2020): $1M backed by PPP
Debt (2021): $990K with participation from PPP
Key Investors in RoosterBio
Vanedge Capital
Vanedge Capital is an early-stage venture capital fund based in Vancouver, Canada, focusing on empowering visionary technologists in the Hard Tech and AI & Analytics sectors.
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies.
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy through biological engineering and production technologies.
What's next for RoosterBio?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the company's product portfolio and deepening its manufacturing capabilities. As the regenerative medicine sector matures, the demand for standardized, GMP-compliant cell manufacturing processes is expected to surge. RoosterBio is strategically aligned to capture this demand by leveraging its existing technological moat and institutional backing. Future growth initiatives will likely prioritize the scaling of production facilities and the integration of advanced analytics to maintain quality control at industrial volumes. With a clear trajectory from early-stage innovation to enterprise-level operations, the company remains a critical component in the global supply chain for advanced biological therapeutics.
See full RoosterBio company page
